Insider Buying: CalciMedica, Inc. (NASDAQ:CALC) Director Purchases 87,744 Shares of Stock

CalciMedica, Inc. (NASDAQ:CALC) Director Fred A. Middleton purchased 87,744 shares of CalciMedica stock in a transaction dated Friday, November 1st. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $329,040.00. Following the transaction, the director now owns 814,300 shares in the company, valued at approximately $3,053,625. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

CalciMedica Stock Performance

CalciMedica stock opened at $3.54 on Wednesday. The company has a market capitalization of $38.06 million, a PE ratio of -2.53 and a beta of 1.30. CalciMedica, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $8.38. The firm has a 50 day moving average price of $4.24 and a 200 day moving average price of $4.63.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. As a group, equities research analysts forecast that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Oppenheimer lifted their target price on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th. HC Wainwright reduced their price objective on shares of CalciMedica from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Monday.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc grew its holdings in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.